Diabetic Ketoacidosis Medical Services in China

Diabetic ketoacidosis (DKA) is a life-threatening acute metabolic complication of diabetes mellitus, predominantly occurring in type 1 diabetes but increasingly recognized in insulin-deficient type 2 diabetes—particularly among individuals of African, Hispanic, or Asian descent. It is characterized by the triad of hyperglycemia (blood glucose >250 mg/dL), metabolic acidosis (arterial pH <7.3 or serum bicarbonate <18 mmol/L), and ketonemia/ketonuria due to severe insulin deficiency and counterregulatory hormone excess (e.g., glucagon, cortisol, catecholamines). Pathogenically, absolute or relative insulin deficiency impairs glucose uptake in muscle and adipose tissue while simultaneously promoting lipolysis and hepatic ketogenesis. Unchecked, this leads to accumulation of acetoacetate, beta-hydroxybutyrate, and acetone—causing osmotic diuresis, profound dehydration, electrolyte derangements (especially potassium, sodium, phosphate), and systemic acidosis. DKA can be precipitated by infection (e.g., pneumonia, UTI), myocardial infarction, stroke, non-adherence to insulin therapy, new-onset diabetes, or use of SGLT2 inhibitors. Epidemiologically, DKA accounts for ~4–8% of all diabetes-related hospitalizations globally; incidence in high-income countries ranges from 1–5 episodes per 1,000 person-years among people with type 1 diabetes. In China, hospitalization rates are rising—driven by delayed diagnosis, limited access to continuous glucose monitoring, and socioeconomic barriers to insulin access. Key risk factors include younger age (<19 years), low socioeconomic status, psychiatric comorbidities (e.g., depression, eating disorders), prior DKA episodes, and lack of structured diabetes education. Untreated or poorly managed DKA carries mortality rates of 1–5% in modern tertiary centers—but rises sharply (>10%) in elderly patients or those with comorbidities like renal failure or sepsis. Beyond acute mortality, recurrent DKA significantly erodes quality of life: patients report chronic fatigue, cognitive fog, anxiety around insulin dosing, fear of hospitalization, disrupted work/school attendance, and strained family dynamics. Long-term consequences include microvascular complications acceleration, increased cardiovascular risk, and reduced health-related quality of life scores (measured by SF-36 or ADDQoL). Early recognition of symptoms—including polyuria, polydipsia, nausea/vomiting, abdominal pain, Kussmaul respirations, fruity breath odor, confusion, or altered mental status—is critical. Prompt emergency intervention—fluid resuscitation, intravenous insulin infusion, careful electrolyte replacement (especially potassium), and identification/treatment of precipitating causes—remains the cornerstone of management. Multidisciplinary follow-up involving endocrinologists, certified diabetes care and education specialists (CDCES), and behavioral health providers is essential to prevent recurrence and optimize long-term outcomes.

Diabetic ketoacidosis (DKA) is a life-threatening acute metabolic complication of diabetes mellitus, predominantly occurring in type 1 diabetes but increasingly recognized in ketosis-prone type 2 diabetes. It is characterized by hyperglycemia (typically blood glucose >250 mg/dL), metabolic acidosis (arterial pH <7.3 or serum bicarbonate <18 mmol/L), and ketonemia/ketonuria due to absolute or relative insulin deficiency, counterregulatory hormone excess, and resultant lipolysis and hepatic ketogenesis. Prompt recognition and standardized management are critical to reduce mortality, which remains 1–5% in high-resource settings but rises significantly with delays in care or comorbidities such as sepsis, acute kidney injury, or cerebral edema.

Conservative treatment forms the cornerstone of DKA management and must be initiated immediately upon diagnosis—ideally in an intensive care or step-down unit with continuous monitoring. The primary goals are: (1) restoration of intravascular volume and tissue perfusion; (2) correction of hyperglycemia and ketosis via insulin therapy; (3) gradual correction of electrolyte deficits—particularly potassium, sodium, and phosphate; and (4) identification and treatment of precipitating factors (e.g., infection, myocardial infarction, nonadherence, new-onset diabetes). Fluid resuscitation begins with isotonic saline (0.9% NaCl) at 15–20 mL/kg over the first hour (≈1–1.5 L in average adults), followed by 4–14 mL/kg/h depending on hemodynamic status, urine output, and serum sodium. Hypotonic fluids (e.g., 0.45% NaCl) may be introduced once serum sodium normalizes and if hypernatremia persists. Careful attention to fluid balance is essential to avoid pulmonary edema or exacerbation of cerebral edema—especially in pediatric patients or those with chronic hyponatremia.

Medication protocols follow evidence-based guidelines from the American Diabetes Association (ADA), European Society of Endocrinology (ESE), and Chinese Diabetes Society (CDS). Intravenous regular insulin is administered as a bolus of 0.1 units/kg, followed by a continuous infusion at 0.1 units/kg/h. Blood glucose should decline by 50–75 mg/dL/h; if not, the infusion rate may be doubled after excluding insulin resistance or infusion line issues. When glucose falls to ≈200 mg/dL (11.1 mmol/L), dextrose (5% or 10%) is added to IV fluids while continuing insulin to prevent hypoglycemia and allow persistent ketosis resolution. Insulin infusion must continue until acidosis resolves (pH ≥7.3 and bicarbonate ≥18 mmol/L), even if glucose normalizes—premature cessation risks rebound ketosis. Potassium replacement is mandatory: if serum K⁺ is <5.3 mmol/L and renal function is adequate (urine output ≥30 mL/h), 20–40 mmol KCl is added per liter of IV fluid. Phosphate replacement (e.g., potassium phosphate 15–30 mmol IV over 6 h) is considered for serum phosphate <1.0 mg/dL or in cases of cardiac dysfunction, rhabdomyolysis, or severe acidosis—but routine use is not recommended due to lack of mortality benefit and risk of hypocalcemia. Bicarbonate therapy remains controversial and is reserved only for life-threatening acidosis (pH <6.9) with hemodynamic instability, given risks of paradoxical CNS acidosis, hypokalemia, and impaired oxygen delivery.

Surgical treatment has no direct role in DKA pathophysiology and is not indicated for DKA itself. However, urgent surgical intervention may be required for underlying precipitants—for example, appendectomy for perforated appendicitis, cholecystectomy for emphysematous cholecystitis, or debridement for necrotizing fasciitis. In rare cases of refractory DKA associated with pheochromocytoma or glucagonoma, tumor resection may be definitive. Additionally, patients with recurrent DKA and suboptimal glycemic control despite education and psychosocial support may be evaluated for advanced technologies—including hybrid closed-loop insulin pump systems—which, while not surgical per se, involve device implantation (e.g., continuous glucose monitor sensors, insulin pump catheters) and require multidisciplinary endocrine-technology team coordination.

Treatment advantages in China reflect robust national infrastructure, policy integration, and innovation in diabetes care. The National Health Commission’s 'Healthy China 2030' initiative prioritizes standardization of acute diabetes care across tertiary hospitals, with over 95% of Grade III-A hospitals implementing CDS-endorsed DKA pathways. Real-time electronic health record alerts trigger automatic DKA order sets, reducing time-to-insulin initiation by 42% in multicenter audits. China leads globally in AI-assisted glucose trajectory prediction: deep learning models integrated into hospital systems forecast DKA risk up to 12 hours before clinical decompensation using continuous glucose monitoring (CGM) and lab data. Furthermore, China’s centralized insulin production ensures stable supply of rapid-acting analogs and regular insulin—critical during regional shortages observed elsewhere. Telemedicine platforms (e.g., WeDoctor, Ping An Good Doctor) enable immediate endocrinology consultation for rural hospitals, shortening transfer times and improving adherence to protocolized care. Importantly, China’s universal health insurance covers CGM, insulin pumps, and emergency hospitalization for DKA without catastrophic out-of-pocket expense—enhancing equity and early intervention.

Recovery advice emphasizes structured transition and long-term prevention. Patients should remain hospitalized until two consecutive venous pH values ≥7.30 and serum bicarbonate ≥18 mmol/L are confirmed, with stable mental status and oral intake tolerance. Transition to subcutaneous insulin requires overlapping IV insulin for ≥2 hours post-first SC dose to prevent rebound ketosis. A basal-bolus regimen (e.g., glargine + rapid-acting analog) is preferred over sliding-scale alone. Comprehensive discharge planning includes individualized sick-day rules: checking blood glucose and urine/ketones every 4 hours during illness; never omitting insulin—even with nausea or reduced intake; consuming carbohydrate-containing fluids (e.g., 15 g carbs/120 mL regular soda) if vomiting is absent; and seeking urgent care if ketones are moderate/large or persist >24 hours. All patients require referral to certified diabetes educators for insulin technique, carbohydrate counting, and CGM training. Psychosocial screening for depression, diabetes distress, and food insecurity is standard in Chinese endocrine departments, with integrated counseling services. Follow-up within 72 hours with an endocrinologist is mandated under CDS quality metrics. Long-term success hinges on addressing root causes: optimizing insulin regimens, mitigating socioeconomic barriers (e.g., subsidized insulin access programs), and leveraging digital tools for real-time remote monitoring. With rigorous adherence to this multimodal approach, recurrence rates drop by >60% at 12 months—underscoring that DKA is not merely an acute crisis, but a sentinel event demanding sustained, patient-centered endocrine stewardship.